CellaVision AB (publ)

OM:CEVI Stock Report

Market Cap: SEK 2.9b

CellaVision Valuation

Is CEVI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of CEVI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: CEVI (SEK120.6) is trading below our estimate of future cash flow value (SEK211.55)

Significantly Below Future Cash Flow Value: CEVI is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CEVI?

Key metric: As CEVI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CEVI. This is calculated by dividing CEVI's market cap by their current earnings.
What is CEVI's PE Ratio?
PE Ratio21.5x
EarningsSEK 134.07m
Market CapSEK 2.88b

Price to Earnings Ratio vs Peers

How does CEVI's PE Ratio compare to its peers?

The above table shows the PE ratio for CEVI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.2x
SUS Surgical Science Sweden
33x28.71%SEK 1.7b
STIL Stille
38.5x22.42%SEK 2.4b
CRAD B C-Rad
38.7x36.60%SEK 1.2b
ARJO B Arjo
18.7x21.32%SEK 6.6b
CEVI CellaVision
21.5x15.01%SEK 2.9b

Price-To-Earnings vs Peers: CEVI is good value based on its Price-To-Earnings Ratio (21.5x) compared to the peer average (32.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does CEVI's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CEVI 21.5xIndustry Avg. 24.6xNo. of Companies11PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CEVI is good value based on its Price-To-Earnings Ratio (21.5x) compared to the European Medical Equipment industry average (25.7x).

Price to Earnings Ratio vs Fair Ratio

What is CEVI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CEVI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.5x
Fair PE Ratio24.9x

Price-To-Earnings vs Fair Ratio: CEVI is good value based on its Price-To-Earnings Ratio (21.5x) compared to the estimated Fair Price-To-Earnings Ratio (24.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CEVI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 120.60
SEK 179.00
+48.42%
14.19%SEK 211.00SEK 140.00n/a4
May ’27SEK 121.20
SEK 179.00
+47.69%
14.19%SEK 211.00SEK 140.00n/a4
Apr ’27SEK 154.20
SEK 228.25
+48.02%
3.58%SEK 235.00SEK 215.00n/a4
Mar ’27SEK 151.80
SEK 228.75
+50.69%
3.58%SEK 235.00SEK 215.00n/a4
Feb ’27SEK 147.40
SEK 225.75
+53.15%
4.18%SEK 235.00SEK 210.00n/a4
Jan ’27SEK 157.20
SEK 228.75
+45.52%
4.98%SEK 240.00SEK 210.00n/a4
Dec ’26SEK 161.40
SEK 228.75
+41.73%
4.98%SEK 240.00SEK 210.00n/a4
Nov ’26SEK 180.00
SEK 230.00
+27.78%
3.07%SEK 235.00SEK 220.00n/a3
Oct ’26SEK 178.20
SEK 225.00
+26.26%
6.85%SEK 240.00SEK 200.00n/a4
Sep ’26SEK 176.20
SEK 225.00
+27.70%
6.85%SEK 240.00SEK 200.00n/a4
Aug ’26SEK 170.60
SEK 225.00
+31.89%
6.85%SEK 240.00SEK 200.00n/a4
Jul ’26SEK 184.60
SEK 227.00
+22.97%
7.36%SEK 245.00SEK 200.00n/a4
Jun ’26SEK 194.40
SEK 230.00
+18.31%
8.13%SEK 250.00SEK 200.00SEK 120.804
May ’26SEK 202.00
SEK 232.00
+14.85%
4.76%SEK 250.00SEK 220.00SEK 121.204
Apr ’26SEK 170.20
SEK 232.50
+36.60%
6.36%SEK 250.00SEK 210.00SEK 154.204
Mar ’26SEK 176.60
SEK 242.50
+37.32%
7.92%SEK 270.00SEK 220.00SEK 151.804
Feb ’26SEK 226.50
SEK 261.25
+15.34%
7.93%SEK 290.00SEK 235.00SEK 147.404
Jan ’26SEK 217.50
SEK 270.00
+24.14%
6.93%SEK 300.00SEK 250.00SEK 157.204
Dec ’25SEK 218.50
SEK 270.00
+23.57%
6.93%SEK 300.00SEK 250.00SEK 161.404
Nov ’25SEK 231.00
SEK 262.50
+13.64%
8.68%SEK 300.00SEK 240.00SEK 180.004
Oct ’25SEK 294.50
SEK 260.50
-11.54%
11.06%SEK 310.00SEK 240.00SEK 178.204
Sep ’25SEK 263.50
SEK 256.75
-2.56%
8.72%SEK 295.00SEK 240.00SEK 176.204
Aug ’25SEK 250.00
SEK 255.50
+2.20%
9.16%SEK 295.00SEK 235.00SEK 170.604
Jul ’25SEK 247.50
SEK 256.25
+3.54%
9.99%SEK 300.00SEK 235.00SEK 184.604
Jun ’25SEK 262.00
SEK 257.50
-1.72%
9.56%SEK 300.00SEK 240.00SEK 194.404
SEK 179
Fair Value
32.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/02 02:00
End of Day Share Price 2026/06/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CellaVision AB (publ) is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bjorn RydellABG Sundal Collier Sponsored
Carl-Oscar BredengenBerenberg
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB